SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCarillion Plc Regulatory News (CLLN)

  • This share is currently suspended. It was suspended at a price of 14.27

Share Price Information for Carillion Plc (CLLN)

Share Price is delayed by 15 minutes
Get Live Data
14.27    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: £61.40m
CLLN Live PriceLast checked at - London Stock Exchange

Intraday Carillion Plc Share Chart

Re Contract

12 May 2014 07:00

RNS Number : 7381G
Carillion PLC
12 May 2014
 

 

12 May 2014

Carillion selected as preferred partner by Network Rail to deliver £100m of track renewal work

Network Rail has announced that over the current five-year funding period, which runs from April 2014 to March 2019, it will renew more than 7,000km of track, as part of a £25bn investment programme.

Carillion has been selected as one of three preferred partners to deliver plain line track renewals. The regions in which Carillion will deliver renewals include the Midlands into the North West, and from Kings Cross to the North East of England. This work is expected to be worth approximately £100 million to Carillion over the five year period for which we expect to sign the contract in June 2014.

Steve Featherstone, Network Rail track programme director, said: "Today, there are a million more trains on our network than a decade ago and that number increases every year. Working with our delivery partners, we will deliver a massive programme of work to maintain, renew and enhance thousands of miles of track over the next five years, with the goal of providing a more reliable railway for passengers and freight."

Carillion Chief Executive, Richard Howson, said: "We are delighted to have been selected for this major programme of track renewals. As one of Network Rail's largest suppliers, we look forward to building on our strong relationship by working in partnership to deliver these important enhancements in order to keep pace with demand and to supporting Network Rail in achieving its objectives of creating a more reliable railway for passengers and freight."

Notes to Editors

Carillion is a leading integrated support services company with a substantial portfolio of Public Private Partnership projects and extensive construction capabilities. The Group had annual revenue in 2013 of some £4.1 billion, employs around 40,000 people and operates across the UK, in the Middle East and Canada.

The Group has four business segments.

Support services - this includes facilities management, facilities services, energy services, utility services, road maintenance, rail services and consultancy services.

 

Public Private Partnership (PPP) projects - this includes investing activities in PPP projects for Government buildings and infrastructure, mainly in the Defence, Health, Education, Transport and Secure accommodation sectors.

Middle East construction services - this includes building and civil engineering activities in the Middle East.

Construction services (excluding the Middle East) - this includes building, civil engineering and developments activities in the UK and construction activities in Canada.

This and other Carillion news releases can be found at www.carillionplc.com

For more information

John Denning, Director Group Corporate Affairs, Carillion plc + 44 (0) 1902 316426

Finsbury

James Murgatroyd or Gordon Simpson +44 (0) 207 2513801

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTLLFSFERIAIIS
Date   Source Headline
3rd Apr 20187:30 amRNSUpdate re Liquidation of Carillion
19th Mar 20187:00 amRNSFRC investigation
17th Jan 20188:15 amRNSAnnouncement Re. Carillion PLC
15th Jan 20187:45 amRNSSuspension - Carillion PLC
15th Jan 20187:00 amRNSCompulsory liquidation of Carillion
12th Jan 20186:08 pmRNSUpdate on discussions with creditors
12th Jan 20185:08 pmRNSHolding(s) in Company
10th Jan 20185:48 pmRNSHolding(s) in Company
9th Jan 20187:03 amRNSResponse to share price movement
3rd Jan 20184:44 pmRNSHolding(s) in Company
3rd Jan 20187:00 amRNSRegulatory investigation
22nd Dec 20177:00 amRNSUpdate on financial covenant deferral
20th Dec 201710:16 amRNSBlock listing Interim Review
20th Dec 20177:00 amRNSChief Executive Appointment
13th Dec 20177:00 amRNSUpdate on UK healthcare facilities business
11th Dec 20177:58 amRNSHolding(s) in Company
1st Dec 20177:00 amRNSDirectorate Change
23rd Nov 201712:08 pmRNSHolding(s) in Company
22nd Nov 201712:29 pmRNSHolding(s) in Company
21st Nov 20174:11 pmRNSHolding(s) in Company
20th Nov 20177:00 amRNSFramework Award
17th Nov 20177:02 amRNSUpdate
15th Nov 20177:00 amRNSOman - letter of award for contract
6th Nov 20177:00 amRNSContract wins
2nd Nov 20177:00 amRNSDirectorate Change
31st Oct 20177:00 amRNSDisposal
27th Oct 20177:00 amRNSChief Executive Appointment
24th Oct 20177:00 amRNSUpdate on financing, disposals and work winning
12th Oct 201712:43 pmRNSUK Healthcare business
4th Oct 20172:58 pmRNSHolding(s) in Company
29th Sep 20177:00 amRNSHalf-year Report
22nd Sep 20171:00 pmRNSHolding(s) in Company
19th Sep 20174:55 pmRNSHolding(s) in Company
11th Sep 20177:00 amRNSDirectorate Change
22nd Aug 20173:17 pmRNSAnnouncement of 2017 interim results
17th Aug 20174:19 pmRNSHolding(s) in Company
15th Aug 20175:58 pmRNSHolding(s) in Company
11th Aug 20176:20 pmRNSHolding(s) in Company
8th Aug 20173:59 pmRNSHolding(s) in Company
8th Aug 201710:02 amRNSHolding(s) in Company
3rd Aug 20179:02 amRNSHolding(s) in Company
1st Aug 201712:24 pmRNSHolding(s) in Company
31st Jul 20172:57 pmRNSHolding(s) in Company
27th Jul 20176:28 pmRNSHolding(s) in Company
18th Jul 201710:49 amRNSHolding(s) in Company
18th Jul 20177:00 amRNSCarillion JV awarded two further HESTIA contracts
17th Jul 20177:19 amRNSHS2 Contract Award
17th Jul 20177:00 amRNSCarillion appoints EY to support strategic review
14th Jul 201712:20 pmRNSHolding(s) in Company
14th Jul 20177:00 amRNSAppointment of Joint Financial Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.